Experience

Affimed
• Germany
• Biotechnology Research
• 100 - 200 Employee
• Head In Vivo Pharmacology

  • Nov 2021 - Present


Bavarian Nordic

• Denmark
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Manager Immunology Research

  • Apr 2019 - Nov 2021

  Department lead in the discovery, research and preclinical development of novel vaccine platforms to enhance immune responses against diverse infectious diseases and cancer.

• Senior Scientist, Immunology Research

  • Sep 2015 - Mar 2019

  Set up the Immuno-Oncology Preclinical Research program at Bavarian Nordic. In vivo and in vitro screening of proprietary viral vector platforms. Identification and validation of targets with potential therapeutic activity. Deep understanding of the underlying mechanism of action in preclinical research models. Filing of intellectual property.



National Cancer Institute, National Institutes of Health

• Research Services
• 1 - 100 Employee

• Postdoctoral Fellow

  • Jul 2012 - Aug 2015

  Role of tumor-induced myeloid cells in the liver microenvironment. Emphasis on the impact of inflammation on the myeloid cell compartment. Analysis of the interplay between tumor-derived factors and myeloid cells in tumor-induced immune suppression. Impact of antibody therapy in the liver microenvironment. Comprehensive study of gut-derived microbiota, immunity and the liver. Role of tumor-induced myeloid cells in the liver microenvironment. Emphasis on the impact of inflammation on the myeloid cell compartment. Analysis of the interplay between tumor-derived factors and myeloid cells in tumor-induced immune suppression. Impact of antibody therapy in the liver microenvironment. Comprehensive study of gut-derived microbiota, immunity and the liver.



Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra

• Research fellow

  • Dec 2011 - Jul 2012

  R&D of apolipoprotein-based molecular scaffolds to improve half life in circulation and targeting of immunomodulatory molecules such as cytokines or peptides.Assessment of the impact of adeno-associated virus as gene therapy vectors on preclinical models of HBV and colon cancer metastases.

• PHD Graduate Student

  • Oct 2007 - Nov 2011

  Development of therapeutic regimes combining chemotherapy and immunotherapy to boost antitumor immunity resulting in tumor rejection.Detailed analysis of the impact of immunomodulatory therapies on the tumor microenvironment. Special emphasis on tumor-derived myeloid cells and Treg.R&D of apolipoprotein-based molecular scaffolds to improve half life in circulation and targeting of immunomodulatory molecules such as cytokines or peptides.